Johnson & Johnson vs Pacific Biosciences of Californ — Stock Comparison
Q·Score Breakdown
7.1
Bullish
Overall
5.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
PACB
Revenue expanding at 14% year-over-year.
⚠ low return on equity (-213%).
Analyst Consensus
BUY
Target $252.42 (+11.1%)
24 analysts
HOLD
Target $2.38 (+48.4%)
6 analysts
Fundamentals
JNJ
PACB
26.3×
Trailing P/E
—
17.9×
Forward P/E
-3.8×
21.8%
Profit Margin
0.0%
68.0%
Gross Margin
34.3%
26.4%
ROE
-213.5%
9.9%
Revenue Growth
13.8%
-52.9%
Earnings Growth
—
0.33
Beta
2.33
—
Price / Book
—
$546.9B
Market Cap
$497M
$146 – $252
52-Week Range
$1 – $3
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →